Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 7/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27573515 | 1.00 | LTA4H (0.51) | LTA4HDRD4SIGMAR1TMEM97TACR1 | |
| SCHEMBL5372336 | 0.91 | LTA4H (0.51) | LTA4HDRD4SIGMAR1TACR1LMNA | |
| SCHEMBL27573483 | 0.91 | LTA4H (0.51) | LTA4HDRD4SIGMAR1TACR1LMNA | |
| SCHEMBL7826831 | 0.89 | LTA4H (0.54) | LTA4HDRD4SIGMAR1TACR1LMNA | |
| SCHEMBL6133201 | 0.89 | LTA4H (0.54) | LTA4HDRD4SIGMAR1TACR1LMNA | |
| SCHEMBL4289658 | 0.89 | LTA4H (0.54) | LTA4HDRD4SIGMAR1TACR1POLB | |
| Hydrochloric Acid SCHEMBL8120467 | 0.88 | LTA4H (0.53) | LTA4HDRD4SIGMAR1TACR1LMNA | |
| Hydrochloric Acid SCHEMBL6132478 | 0.88 | LTA4H (0.53) | LTA4HDRD4SIGMAR1TACR1LMNA | |
| SCHEMBL22079729 | 0.85 | DRD4 (0.38) | LTA4HDRD4SIGMAR1TMEM97TACR1 | |
| SCHEMBL5370269 | 0.85 | LTA4H (0.51) | LTA4HDRD4SIGMAR1TACR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-7166598-B2 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| CN-1152877-C | Piperazine derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | LTA4H 944/4885DRD4 1628/4885SIGMAR1 803/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | LTA4H 677/4885DRD4 752/4885SIGMAR1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.